2021 Updates: Lilly's Global COVID-19 Response

NOTE: For more information about Lilly's COVID-19 therapies authorized for emergency use, contact the Lilly COVID Hotline at 1-855-LillyC19 (1-855-545-5921).

Lilly continues to closely monitor the COVID-19 pandemic and its global impact. As this is an evolving topic, Lilly will include relevant announcements and information on this page.

• If the COVID-19 pandemic has impacted your ability to afford or access your Lilly medicine, contact us via these options.

• If you have questions about a Lilly medicine, call The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979). See more information about TLAC.

• If you have insulin access and affordability questions, call the Lilly Diabetes Solution Center at 1-833-808-1234. See more information about the LDSC.

• For Indiana residents: Lilly is not currently offering COVID-19 drive-through testing to the public. Please visit info.covid19testing.lilly.com for more information on COVID-19 testing in Indiana.

• Centers for Disease Control information can be found at cdc.gov/coronavirus.

• Visit combatcovid.hhs.gov to find out more about antibody therapy.

• Patients and physicians can visit covid.infusioncenter.org or the U.S. Health & Human Services (HHS) Therapeutics Distribution locator to find a potential treatment location near you.

• Lilly values high-quality medical education and is a proud supporter of COVID-related, accredited Independent Medical Education (IME), which includes a mix of live and enduring formats. View U.S.-specific 2021 IME opportunities.

• Read Lilly's COVID-19 fact sheet.

On COVID-19 and Clinical Trials:

• If you are a clinical investigator, or you represent a hospital or clinical site, and are interested in participating as an investigator or site in one of Lilly’s clinical trials for a potential COVID-19 treatment, call 1-877-CT-LILLY (1-877-285-4559) or email covid19potentialsite@lilly.com.

• Patients interested in participating in one of our clinical trials for a potential COVID-19 treatment should visit Lilly TrialGuide for information regarding eligibility for ongoing trials.

Here’s what we’re doing to ensure people have access to Lilly medicines:

News Releases, Resources and Multimedia

March

• COVID-19 antibody allocation and transparency tracker

February

• Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19 (February 26)

• Lilly’s bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA Emergency Use Authorization for COVID-19 (February 9)

• Lilly partners with area health systems to help enable access to important antibody infusion therapies for COVID-19 patients (February 1)

January

• Lilly's operations guide about infusion units for COVID-19 antibody treatment and COVID antibody infusion clinic learnings

• Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19 (January 27)

• New data show treatment with Lilly’s neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent (January 26)

• Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents (January 21)

• Article: "Could monoclonal antibodies help in your COVID-19 treatment journey?" (January 15)

All-Updates Timeline

March 2, 2021

Today we published a COVID-19 antibody allocation and transparency tracker. Lilly is working with global regulators to make our neutralizing antibody available for emergency use in countries around the world.

February 26, 2021

Lilly announced an agreement with the U.S. government to provide a minimum of 100,000 doses of our investigational neutralizing antibodies administered together for the treatment of mild to moderate COVID19 in high-risk patients.

February 9, 2021

Today we announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for investigational bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together. This therapy is authorized for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization.

January 28, 2021

Lilly is partnering with Indiana health systems to launch pilot infusion center locations serving central, northern, and now southern parts of the state. These are intended to provide Hoosiers with access to important COVID-19 treatments. Multiple neutralizing antibody therapies have been granted Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in high-risk patients.

Additionally, Lilly has published an operations guide about infusion units for COVID-19 antibody treatment and COVID antibody infusion clinic learnings.

January 27, 2021

Lilly, Vir Biotechnology and GlaxoSmithKline (GSK) announced a collaboration to evaluate a combination of two therapies in low-risk patients with mild to moderate COVID-19. This unique collaboration, combining monoclonal antibodies from separate companies, is designed to explore whether clinical outcomes can be further improved.

January 26, 2021

Lilly shared today that new Phase 3 trial data show our neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with COVID-19.

January 21, 2021

Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Lilly announced today. The BLAZE-2 COVID-19 prevention trial – conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN) – enrolled residents and staff at skilled nursing and assisted living facilities, commonly referred to as nursing homes, across the U.S.

Patients and physicians can visit covid.infusioncenter.org or the HHS Therapeutics Distribution locator to find a potential treatment location near you.

January 15, 2021

If a high-risk patient tests positive for COVID-19 and has mild-to-moderate symptoms, new monoclonal antibody treatments could provide real help – not just hope. To learn more, visit combatcovid.hhs.gov.

2020 Highlights

• Data from ACTT-2 trial of baricitinib in hospitalized COVID-19 patients supportive of the EUA published in New England Journal of Medicine (December 11)

• Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19 (December 2)

• Baricitinib receives Emergency Use Authorization by the U.S. Food and Drug Administration for the treatment of hospitalized patients with COVID-19 (November 19)

• Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA Emergency Use Authorization for the treatment of recently diagnosed COVID-19 (November 9)

• Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19 (October 28)

• Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 patients published in New England Journal of Medicine (October 28)

Learn more about Lilly's 2020 efforts to fight COVID-19.

Note: The FDA grants Emergency Use Authorization to provide availability of a medicine that may help diagnose, treat or prevent a life-threatening disease when no adequate and approved alternatives are available.